164 related articles for article (PubMed ID: 11012295)
1. Changing strategies for treatment of systemic mycoses.
Graybill JR
Braz J Infect Dis; 2000 Apr; 4(2):47-54. PubMed ID: 11012295
[TBL] [Abstract][Full Text] [Related]
2. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
3. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
4. Antifungal treatment in patients with cancer.
Viscoli C; Castagnola E; Machetti M
J Intern Med Suppl; 1997; 740():89-94. PubMed ID: 9350188
[TBL] [Abstract][Full Text] [Related]
5. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
6. Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins MD; Rex JH
New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in antifungal chemotherapy.
Petrikkos G; Skiada A
Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
[TBL] [Abstract][Full Text] [Related]
8. Strategies for managing systemic fungal infection and the place of itraconazole.
Potter M
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
[TBL] [Abstract][Full Text] [Related]
9. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
10. Treatment of systemic mycoses in patients with AIDS.
Graybill JR
Arch Med Res; 1993; 24(4):403-12. PubMed ID: 8118165
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
Karthaus M; Böhme A
Wien Med Wochenschr; 2001; 151(3-4):80-8. PubMed ID: 11789423
[TBL] [Abstract][Full Text] [Related]
12. [Future directions of antimycotic therapy].
Meunier F
Mycoses; 1994; 37 Suppl 2():77-82. PubMed ID: 7541893
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
14. [New aspects in treatment of systemic mycoses].
Presterl E; Graninger W
Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
[TBL] [Abstract][Full Text] [Related]
15. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
Seifert H; Aurbach U; Stefanik D; Cornely O
Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B: what is its role in 2008?
Lanternier F; Lortholary O
Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
[TBL] [Abstract][Full Text] [Related]
19. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
20. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Carlyn CJ; Michelsen PB
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):299-304. PubMed ID: 15893901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]